- Home
- UEIC vs KLRS Comparison
UEIC vs KLRS Comparison
Compare UEIC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEIC
- KLRS
- Stock Information
- Founded
- UEIC 1986
- KLRS 2019
- Country
- UEIC United States
- KLRS United States
- Employees
- UEIC N/A
- KLRS N/A
- Industry
- UEIC Consumer Electronics/Appliances
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UEIC Consumer Staples
- KLRS Health Care
- Exchange
- UEIC Nasdaq
- KLRS Nasdaq
- Market Cap
- UEIC 47.7M
- KLRS 46.0M
- IPO Year
- UEIC 1993
- KLRS N/A
- Fundamental
- Price
- UEIC $3.54
- KLRS $4.78
- Analyst Decision
- UEIC Buy
- KLRS Strong Buy
- Analyst Count
- UEIC 2
- KLRS 3
- Target Price
- UEIC $10.00
- KLRS $21.50
- AVG Volume (30 Days)
- UEIC 97.2K
- KLRS 109.9K
- Earning Date
- UEIC 11-06-2025
- KLRS 11-24-2025
- Dividend Yield
- UEIC N/A
- KLRS N/A
- EPS Growth
- UEIC N/A
- KLRS N/A
- EPS
- UEIC N/A
- KLRS N/A
- Revenue
- UEIC $390,997,000.00
- KLRS N/A
- Revenue This Year
- UEIC $0.57
- KLRS N/A
- Revenue Next Year
- UEIC N/A
- KLRS N/A
- P/E Ratio
- UEIC N/A
- KLRS N/A
- Revenue Growth
- UEIC 2.35
- KLRS N/A
- 52 Week Low
- UEIC $3.03
- KLRS $2.14
- 52 Week High
- UEIC $12.50
- KLRS $23.69
- Technical
- Relative Strength Index (RSI)
- UEIC 26.82
- KLRS 47.17
- Support Level
- UEIC $4.34
- KLRS $4.67
- Resistance Level
- UEIC $3.96
- KLRS $5.10
- Average True Range (ATR)
- UEIC 0.21
- KLRS 0.41
- MACD
- UEIC -0.07
- KLRS -0.03
- Stochastic Oscillator
- UEIC 31.72
- KLRS 39.41
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.